iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

The fall from glory for Ibio stock is probably just getting started. As such, most investors should avoid it at all cost, despite the hype.

Ibio Stock Is a Long Shot That’s Only Suited for Speculators

NEW YORK, March  26, 2020  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced that it has entered into a second Statement of Work under its Master Joint Development Agreement (the “MJDA”) with AzarGen Biotechnologies (Pty.) Ltd. (“AzarGen”).  Signed in 2018, the MJDA contemplates initial contract development and manufacturing of AzarGen’s biosimilars at iBio’s Bryan, Texas facility. Ultimately, iBio plans to transfer its proprietary  FastPharming  Manufacturing System™ to AzarGen in South Africa for production of critical biological medicines for the African continent.

iBio Supporting AzarGen Biotechnologies’ Development of a Rituximab Biosimilar

- Preclinical Immunization Studies at Texas A&M University - - Preclinical Immunization Studies at Texas A&M University -

iBio Announces Advancement of COVID-19 Vaccine Program

Don’t let me talk you out of iBio stock, but a bit of skepticism is required given the massive hype behind this bio-pharmaceutical COVID-19 play.
The post It’s Time for Investors to Run Far Away From iBio Stock appeared first on InvestorPlace.

It’s Time for Investors to Run Far Away From iBio Stock

Underscoring the volatility associated with companies purporting to be on the cusps of cures or treatments for international pandemics, IBIO has more than quadrupled just this month, but the stock resides 63.53% below the 52-week high notched in early March.
The post iBio Stock Isn’t the Coronavirus Play Investors Want It to Be appeared first on InvestorPlace.

iBio Stock Isn’t the Coronavirus Play Investors Want It to Be

IBIO stock looked trapped. But a new partnership and vaccine tech offers a promising coronavirus solution and big gains.

Top-Notch Vaccine Technology Makes iBio Stock a Smart Bet

iBio, Inc.: Future Prospects

The recent market meltdown has wrecked havoc on portfolios. But it's also given investors the opportunity to buy high quality stocks selling at low valuations.

Don’t Waste Time and Risk Capital on Coronavirus Play IBIO Stock

NEW YORK, March  20, 2020  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biologics contract manufacturing organization and biotechnology company, today announced that it has joined the Alliance for Biosecurity, a coalition of biopharmaceutical companies – along with laboratory and academic partners – that promotes a strong public-private partnership in order to ensure the medical countermeasures that protect public health are effective and readily available.

iBio Joins the Alliance for Biosecurity

After years trading with penny status, IBIO stock needs more than just a coronavirus vaccine to sustain its surge.
The post Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play appeared first on InvestorPlace.

Coronavirus-Fighting Tech Makes iBio Stock an Interesting Play

Several Provisional Patents Filed with USPTO Several Provisional Patents Filed with USPTO

iBio Announces Development of Proprietary COVID-19 Vaccine Candidates

IBIO stock has soared on hopes for a coronavirus vaccine. But similar theses in the past have led to huge losses.

We’ve Seen the iBio Stock Story Before — And It Doesn’t End Well

And, yet, you won’t see Buffett buying iBio despite the fact it’s working on a coronavirus vaccine. You won’t for several primary reasons.

I Doubt You’ll See Warren Buffett Buying IBIO Stock

IBIO stock is a big winner today thanks to the rapidly spreading coronavirus outbreak, but the longevity of this rally is at question.
The post iBio Stock Is Unlikely a Coronavirus Winner and Thus a Real Gamble appeared first on InvestorPlace.

iBio Stock Is Unlikely a Coronavirus Winner and Thus a Real Gamble

NEW YORK, March  12, 2020  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today announced the appointment of accomplished life sciences executive, Thomas F. Isett, as its Co-Chairman and Chief Executive Officer. Mr. Isett, a current member of iBio’s Board of Directors, succeeds Robert B. Kay, who has retired from the role as Chief Executive Officer, but will remain as Co-Chairman and member of the Board.

iBio Announces Leadership Succession, Appoints Thomas F. Isett Co-Chairman & CEO

Unless there are positive updates regarding a potential coronavirus vaccine soon, the run for new highs may be over in IBIO stock for now.
The post Why iBio Pharma Stock Is Not for Timid Investors Despite Great Potential appeared first on InvestorPlace.

Why iBio Pharma Stock Is Not for Timid Investors Despite Great Potential

One of the few beneficiaries of the coronavirus are pharmaceutical firms that may offer a solution. But with IBIO stock and similar names, the upside pathway may not be as limited as previously thought.

IBIO Stock May Have a Longer ‘Trial Period’

Shares of tiny biotech iBio Inc. IBIO, +22.03% surged another 19% in premarket trade Thursday, on continued strong hopes for its partnership with a Chinese company on a plant-based vaccine to treat the coronavirus.

iBio stock surges 19% premarket on hopes for plans to develop plant-based coronavirus vaccine

NEW YORK, March  02, 2020  (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that its Board of Directors has decided it will not seek authority from the shareholders at the 2019 Annual Meeting (“Annual Meeting”) to effect a reverse split of its issued and outstanding shares of common stock and, accordingly, Proposal No. 5 in the Definitive Proxy Statement filed with the Securities and Exchange Commission on January 23, 2020 (the “Proxy Statement”) for such authority has been withdrawn from the agenda for the Annual Meeting.

iBio, Inc. Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split

iBio Pharma (IBIO) stock is blasting off on Friday as fears of the coronavirus from China continue to grow and it works on a vaccine.

iBio Pharma Stock: 8 Things for Investors to Know as Shares Soar 181%

Shares of iBio Inc.  soared another 174% Friday, bringing their weekly gain to 689%, on hopes for the company's partnership with Beijing CC-Pharming Ltd.

iBio shares soar another 174% on hopes for China vaccine partnership

NEW YORK, Feb.  06, 2020  (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that the 2019 annual meeting of stockholders (the “Annual Meeting”) originally scheduled to be held on Monday, February 10, 2020, has been postponed and will now be held on March 5, 2020, at 9:30 a.m. ET.

iBio, Inc. Announces Postponement of Annual Meeting

NEW YORK, Feb.  03, 2020  (GLOBE NEWSWIRE) -- In response to investor and media inquiries regarding their initiatives to address the coronavirus outbreak, iBio, Inc. (NYSE AMERICAN:IBIO) and Beijing CC-Pharming Ltd., today announced their collaboration to develop and test a new 2019-nCoV vaccine to be manufactured using iBio’s     FastPharming     System™. The companies are expediting work as  predictions  about spread of the disease continue to worsen.

iBio and CC-Pharming Initiate Joint Development of Coronavirus Vaccine

NEW YORK, Jan.  16, 2020  (GLOBE NEWSWIRE) -- IBIO, INC. (NYSE AMERICAN: IBIO) (“IBIO” OR THE “COMPANY”), today announced that it has received notice from NYSE American LLC (the “Exchange”) that NYSE Regulation has accepted the Company’s November 15, 2019 plan to regain compliance with the Exchange’s continued listing standards set forth in Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) and has granted a plan period through December 9, 2020, subject to periodic review by the Exchange, including quarterly monitoring, for compliance with the initiatives outlined in the plan. If the Company is not in compliance with the continued listing standards by December 9, 2020, or if the Company does not make progress consistent with the plan during the plan period, the NYSE Regulation staff will initiate delisting proceedings as appropriate.

iBio, Inc. Announces NYSE American Acceptance of Plan of Compliance

NEW YORK, Jan.  07, 2020  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio”), a biologics innovator and contract manufacturer, announced today that it filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft (“Fraunhofer”) through an amended complaint. The new motion asserts that depositions conducted in late 2019 of personnel of Fraunhofer and its U.S. unit, Fraunhofer USA, Inc. (“FhUSA”), revealed that Fraunhofer exercised complete dominion and control over FhUSA to wrongfully access and direct use of iBio’s intellectual property on many occasions with new and different third parties. 

News for iBio Stock (IBIO)